CAMBRIDGE, Mass., Oct. 29, 2012 /PRNewswire-USNewswire/ -- Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, today announced its participation in four upcoming conferences.
- 2012 New York CEO Biotech Conference at the Apella in New York, NY on Thursday, November 1st, at 5:00 p.m. ET
- 2nd Cancer Epigenetics Conference at the Park Plaza Hotel & Towers in Boston, Mass. on Friday, November 9th, for the keynote speech at 8:35 a.m. ET
- Lazard Capital Markets 9th Annual Healthcare Conference at the Pierre Hotel in New York, NY on Tuesday, November 13th, at 2:00 p.m. ET
- Piper Jaffray 24th Annual Healthcare Conference at the New York Palace Hotel in New York, NY on Tuesday, November 27th, at 10:30 a.m. ET
"Epizyme looks forward to meeting with the scientific community and investors to present our focused approach to the development of personalized therapeutics and companion diagnostics to treat genetically defined cancers," said Robert Gould, President and CEO, Epizyme. "Presenting the foundations of our clinical platform, we'll address how our focus on the genetic drivers of cancer leads to quicker, more efficient drug development, pairing the right medicines with the right patients to create a personalized approach to cancer treatment."
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.